Letter: Vonoprazan, a long-lasting acid suppressor of the gastric H+, K+-ATPases with - Implications for renal H+, K+-ATPases

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 3, 2016, Pages 442-443

  Srinivas, N R ^a  

^a Suramus Bio   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; POTASSIUM ION; PROTON PUMP INHIBITOR; SODIUM ION; VONOPRAZAN; PYRROLE DERIVATIVE; SULFONAMIDE;

ACID BASE BALANCE; DRUG ACCUMULATION; DRUG POTENCY; DRUG RETENTION; GASTROINTESTINAL TRACT; HUMAN; LETTER; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH PARIETAL CELL; ANIMAL; MALE; METABOLISM; STOMACH;

ANIMALS; H(+)-K(+)-EXCHANGING ATPASE; MALE; PROTON PUMP INHIBITORS; PYRROLES; STOMACH; SULFONAMIDES;

EID: 84955263713     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13482     Document Type: Letter

References (7)

1. Hori Y, Imanishi A, Matsukawa J, et al,. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-Nmethylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 2010; 335: 231-8.
2. Shin JM, Inatomi N, Munson K, et al,. Characterization of a novel potassium competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-fluorophenyl)-1- (pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]- N-methylmethanamin e monofumarate (TAK-438). J Pharmacol Exp Ther 2011; 339: 412-20.
3. Vagin O, Denevich S, Munson K, Sachs G,. SCH28080, a K+-competitive inhibitor of the gastric H, K-ATPase, binds near the M5-6 luminal loop, preventing K+ access to the ion binding domain. Biochemistry 2002; 41: 12755-62.
4. Jenkins H, Sakurai Y, Nishimura A, et al,. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2015; 41: 636-48.
5. Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G,. The binding selectivity of vonoprazan (TAK-438) to the gastric H(+), K(+) -ATPase. Aliment Pharmacol Ther 2015; 42: 1315-26.
6. Gumz ML, Lynch IJ, Greenlee MM, Cain BD, Wingo CS,. The renal H+-K+-ATPases: physiology, regulation, and structure. Am J Physiol Renal Physiol 2010; 298: F12-21.
7. Echizen H,. The First-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2015; [Epub ahead of print]